GSK Boosts Blenrep’s Resurgence with Successful Second Phase III Trial
- **Company**: GlaxoSmithKline (GSK)
- **Product**: Blenrep
- **News**: Positive data reported from a second Phase III clinical trial for Blenrep
- **Comeback Potential**: This news suggests a potential rebound for Blenrep, which previously faced setbacks
- **Date**: Information released on March 15, 2024